Elevated of Biomarker NT-proBNP Liked To Cardiac Fibrosis

MedicalResearch.com Interview with:

David A. Bluemke, MD PhD, MsB Professor, Radiology Editor in Chief (2018), Radiology University of Wisconsin-Madison, School of Medicine and Public Health Madison WI 53792

Dr. Bluemke

David A. Bluemke, MD PhD, MsB
Professor, Radiology
Editor in Chief (2018), Radiology
University of Wisconsin-Madison,
School of Medicine and Public Health
Madison WI 53792 

MedicalResearch.com: What is the background for this study? What are the main findings?

Response: Heart failure is expected to markedly increase in the United States, because of the aging population (https://www.ncbi.nlm.nih.gov/pubmed/23616602. For patients with congestive heart failure, NT-proBNP is an excellent marker of disease severity. The presence of elevated levels of NT-proBNP also predicts future cardiac events.

For individuals who do not have clinically diagnosed heart failure, the significance of small elevations in NT-proBNP is not known. We hypothesized that these small elevations were related to subclinical elevations in myocardial wall stress. However, in patients with advanced heart disease, we do know that greater myocardial wall stress is associated with histological evidence of fibrosis — i.e., replacement of myocardial muscle by greater fibrotic tissue.

New techniques using MRI can find evidence of expansion of the space between myocytes (the extracellular volume). The most common cause of this expansion is diffuse myocardial fibrosis/ collagen deposition. Using MRI to detect myocardial fibrosis is an advance because MRI is non-invasive (we would not otherwise perform myocardial biopsy for patients without clinically evident disease). Thus we can use MRI to probe the actual composition of myocardial tissue.

Using MRI, we found evidence that individuals in the community (in the MESA study) who had small elevations of NT-proBNP also have evidence of myocardial fibrosis.   The mean NT-proBNP levels in the MESA study (1,334 study subjects) was 65 pg/ml. That level is considered to be normal; levels of NT-proBNP of 1200 pg/ ml or greater are found in patients with congestive heart failure.

Of note, the relationship between elevations of NT-proBNP and myocardial fibrosis were independent of multiple risk factors such as age, gender, smoking status, blood pressure, cholesterol levels and diabetes. That is, if the NT-proBNP level was slightly higher (for example, due to increased wall stress), then MRI found an association with greater myocardial fibrosis.

MedicalResearch.com: What should readers take away from your report?

Response: Myocardial fibrosis is a basic response of the heart to a variety of myocardial injuries, including increased myocardial wall strain. At a histological level, greater wall strain is increased collagen deposition. Our study highlights that subclinical – even within the high, normal range – of NT-proBNP level is associated with evidence of adverse myocardial remodeling that can be detected non-invasively.

MedicalResearch.com: What recommendations do you have for future research as a result of this study?

Response: This study emphasizes the high degree of sensitivity of serum biomarkers such as NT-proBNP. Adverse myocardial remodeling takes place even at relatively low levels of that marker. Our study results were achieved when we evaluated more than 1000 individuals: unfortunately we cannot yet apply these results to the individual patient in our office. However, our results emphasize the need for medications targeted towards reversing myocardial remodeling and emphasizing known risk factors such as hypertension and diabetes. 

No disclosures

MedicalResearch.com: Thank you for your contribution to the MedicalResearch.com community.


Association of Elevated NT-proBNP With Myocardial Fibrosis in the Multi-Ethnic Study of Atherosclerosis (MESA)
Chia-Ying LiuSusan R. HeckbertShenghan LaiBharath Ambale-VenkateshMohammad R. OstovanehRobyn L. McClellandJoão A.C. Lima and David A. Bluemke

Note: Content is Not intended as medical advice. Please consult your health care provider regarding your specific medical condition and questions.







Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.